Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
APLT | US
-0.69
-8.22%
Healthcare
Biotechnology
30/06/2024
04/10/2024
7.70
7.94
8.07
7.57
Applied Therapeutics Inc. a clinical-stage biopharmaceutical company develops novel products to target central nervous system rare disease and diabetic complications in the United States. Its lead product candidate is AT-007 that has completed phase III for the treatment of galactosemia in healthy volunteers and adults as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials to treat diabetic cardiomyopathy as well as for the treatment of diabetic peripheral neuropathy; and AT-003 which is in preclinical studies for the treatment diabetic retinopathy. Applied Therapeutics Inc. was incorporated in 2016 and is headquartered in New York New York.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
61.5%1 month
243.9%3 months
155.3%6 months
116.7%-
-
13.12
0.00
0.00
-9.71
62.37
-
-78.03M
884.31M
884.31M
-
-14.19K
-
-98.20
-473.39
10.18
10.53
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.39
Range1M
4.35
Range3M
4.59
Rel. volume
0.21
Price X volume
7.67M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Sana Biotechnology Inc. Common Stock | SANA | Biotechnology | 4.23 | 941.03M | -2.98% | n/a | 29.02% |
Silence Therapeutics plc | SLN | Biotechnology | 18.64 | 933.49M | 1.30% | n/a | 0.16% |
Prothena Corporation plc | PRTA | Biotechnology | 16.86 | 906.74M | 1.08% | n/a | 2.08% |
Zymeworks Inc | ZYME | Biotechnology | 12.57 | 893.07M | 1.45% | n/a | 4.94% |
Cronos Group Inc | CRON | Biotechnology | 2.24 | 856.31M | 3.70% | n/a | 0.19% |
iShares $ Corp Bond ETF USD Dist | LQDA | Biotechnology | 10.03 | 846.31M | 0.25% | n/a | 4.70% |
CARGO Therapeutics Inc. Common Stock | CRGX | Biotechnology | 17.77 | 815.72M | -1.44% | n/a | 6.45% |
Adeptus Health Inc | ADPT | Biotechnology | 5.52 | 814.05M | 7.39% | n/a | 93.65% |
Nuvation Bio Inc | NUVB | Biotechnology | 2.41 | 806.82M | 9.05% | n/a | 112.61% |
Immunome Inc | IMNM | Biotechnology | 13.17 | 790.92M | -2.44% | n/a | 1.09% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -9.71 | 0.76 | Cheaper |
Ent. to Revenue | 62.37 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 13.12 | 14.10 | Par |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 155.30 | 74.67 | Riskier |
Debt to Equity | 0.00 | -1.82 | Expensive |
Debt to Assets | 0.00 | 0.26 | Cheaper |
Market Cap | 884.31M | 3.73B | Emerging |